My PSA as is starting to rise on Arbi/Dexa. I have the CDK12 mutation which is apparently known to be a drug target or to predict sensitivity to Atezolizumab (Tecentriq PD-1 Checkpoint Inhibitor), hence there is open Immunotherapy trial called BoB (NCT03767075). I meet the trial doctor next week.
I also found an ongoing trial immunotherapy trial IMPACT (NCT03570619) which combines other drugs used for immunotherapy with CDK12 (ie: Nivolumab and Ipilimumab)
Has anyone here in the community had success on either of these trials? For the moment I'm not yet convinced that this is the best "next step" for my Prostate Cancer.
At what point should i really drop the ARBI/Dexa? For the moment my Oncologist has given me another 4-month supply whilst I look around at trials
Written by
MikeMartin
To view profiles and participate in discussions please or .
I don't understand how it is determined that PC is still castrate sensitive if PSA is rising under ADT? This trial is only open to castrate sensitive people.
Thank you for your reply. In addition to what you mentioned, I also found a trial with Darolutamide and Abemaciclib at Dana Farber. classic.clinicaltrials.gov/...
So I have written to the clinical trials co-ordinator at both sites.
To note:
1) The meeting I have on Tuesday is at Gustave Roussy and its call a Basket of Baskets trial - Arm 1G. I suppose they look at repurposing where certain mutations are present.. Here is the link
I thought you were in France. If you can come to the US, there are many clinical trials of abemaciclib, ribociclib, and palbociclib. Abemaciclib is available for breast cancer under the brand name Verzenio, so it is available from your oncologist off-label. Here is my list of current clinical trials:
Well Goustave Roussy is pretty thorough! They want to do their own gene testing on the both the original biopsy from Dec 2020, and another circulating tumor test. If there is not enough evidence to go on they will biopsy the tumor itself. I should get a feed back in 2 or 3 weeks if there is confirmation otherwise, I'm Ok to do another biopsy. It would be nice to have a forum specific area. There is more interest in targeting CDK12 recently and some evidence from Marsden and GR that some PARP inhibitors might make a difference with ENZA
They did another FD One Liquid biopsy and found traces of CDK12. But for the BoB eligibility they’ve asked my primary care provider to do a new biopsy as the original does not have enough material. I’m OK to do this but seeing the comment from Tall_Allen and doing further research I am questioning a little whether Tecentriq on its own will make a difference with this mutation
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Cancer immunotherapy 
Immunotherapy keytruda
Clinical trial / study: BRCA mutations
KEYTRUDA immunotherapy 
Intro and Immunotherapy question
